Dr. Bosse on the Quality of Life With VEGF Plus Radium-223

Dominick Bosse, MD
Published: Tuesday, Oct 17, 2017



Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the quality of life when combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).

There was a secondary endpoint that looked at quality of life, according to Bosse. There was no decrease in pain or improvement of quality of life. This is probably because the entry criteria allowed a maximum of patients with bone disease. The survival of these patients was very short, states Bosse.
 
SELECTED
LANGUAGE


Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the quality of life when combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).

There was a secondary endpoint that looked at quality of life, according to Bosse. There was no decrease in pain or improvement of quality of life. This is probably because the entry criteria allowed a maximum of patients with bone disease. The survival of these patients was very short, states Bosse.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x